PLN and heart failure: With regard to the therapeutic target for heart failure, we chose PP1β, the PP1 isoform of which we previously reported that it dominantly suppresses SR-mediated Ca2+ uptake [25] via PLN dephosphorylation, and its expression has been reported to be upregulated in failing hearts [26].